IPO - Cartesian Therapeutics, Inc.

Form Type: 424B7

Filing Date: 2025-01-08

Corporate Action: Ipo

Type: New

Accession Number: 000114036125000631

Filing Summary: This prospectus relates to the proposed resale of up to 6,251,150 shares of Common Stock by designated Selling Stockholders of Cartesian Therapeutics, Inc. It includes 5,813,223 shares from a Private Placement, and 437,927 shares convertible from Series B Preferred Stock. The Private Placement was completed on July 3, 2024, with the Selling Stockholders retaining the authority to sell the shares in various markets, at fixed or prevailing market prices. The document emphasizes that no proceeds will be received by Cartesian Therapeutics from the sale of these Resale Shares. As of January 7, 2025, the last reported sale price for the Common Stock was $17.16 per share. The prospectus outlines the high-risk factors associated with investing in their securities, indicating a significant exposure to market volatility, regulatory changes, and operational uncertainties. The document further details the corporate structure following the merger agreement, where Cartesian Therapeutics, Inc. was formed after merging with Old Cartesian on November 13, 2023. The prospectus also notes that the Common Stock is listed on the Nasdaq Global Market under the symbol 'RNAC'.

Document Link: View Document